Merck inks MoU with Aragen to facilitate supply of equipment and technologies for mAb
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Subscribe To Our Newsletter & Stay Updated